 DALLAS, May 3, 2021 PRNewswire -- Lantern Pharma Inc. NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform oncology drug discovery and development today announced financial results for the first quarter ended March 31, 2021. 